HETEROGENEITY OF THE EFFECT OF COMBINED FRACTIONATED RADIOTHERAPY AND EGFR/HER2 TYROSINE KINASE INHIBITION

被引：0
|
作者：
Gurtner, K. [1 ,2 ]
Schuetze, C. [1 ,2 ]
Soica, F. [3 ]
Baumann, M. [1 ,2 ]
Krause, M. [1 ,2 ]
机构：
[1] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Fac Med, Dresden, Germany
[2] Tech Univ, Dept Radiat Oncol, OncoRay Ctr Radiat Res Oncol, Univ Hosp Carl Gustav Carus, Dresden, Germany
[3] Boehringer Ingelheim Austria, Vienna, Austria
来源：
RADIOTHERAPY AND ONCOLOGY | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
128
引用
收藏
页码：S42 / S43
页数：2
相关论文
共 50 条
  • [1] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
    Wang, Shizhen Emily
    Narasanna, Archana
    Perez-Torres, Marianela
    Xiang, Bin
    Wu, Frederick Y.
    Yang, Seungchan
    Carpenter, Graham
    Gazdar, Adi F.
    Muthuswamy, Senthil K.
    Arteaga, Carlos L.
    CANCER CELL, 2006, 10 (01) : 25 - 38
  • [2] Lapatinib: A novel EGFR/HER2 tyrosine kinase inhibitor for cancer
    Johnston, Stephen R. D.
    Leary, Alex
    DRUGS OF TODAY, 2006, 42 (07) : 441 - 453
  • [3] Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity
    Montemurro, Filippo
    Valabrega, Giorgio
    Aglietta, Massimo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (02) : 257 - 268
  • [4] Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
    Kim, Hwang-Phill
    Yoon, Young-Kwang
    Kim, Jin-Won
    Han, Sae-Won
    Hur, Hyung-Seok
    Park, Jinah
    Lee, Ju-Hee
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Kim, Tae-You
    PLOS ONE, 2009, 4 (06):
  • [5] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Prasad Sanjay Dhiwar
    Gurubasavaraja Swamy Purwarga Matada
    Nulgumnalli Manjunathaiah Raghavendra
    Abhishek Ghara
    Ekta Singh
    Nahid Abbas
    Ganesh Sakaram Andhale
    Ganesh Prasad Shenoy
    Pujan Sasmal
    Medicinal Chemistry Research, 2022, 31 : 1401 - 1413
  • [6] Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer
    Dhiwar, Prasad Sanjay
    Matada, Gurubasavaraja Swamy Purwarga
    Raghavendra, Nulgumnalli Manjunathaiah
    Ghara, Abhishek
    Singh, Ekta
    Abbas, Nahid
    Andhale, Ganesh Sakaram
    Shenoy, Ganesh Prasad
    Sasmal, Pujan
    MEDICINAL CHEMISTRY RESEARCH, 2022, 31 (09) : 1401 - 1413
  • [7] Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
    Kosaka, Takayuki
    Tanizaki, Junko
    Paranal, Raymond M.
    Endoh, Hideki
    Lydon, Christine
    Capelletti, Marzia
    Repellin, Claire E.
    Choi, Jihyun
    Ogino, Atsuko
    Calles, Antonio
    Ercan, Dalia
    Redig, Amanda J.
    Bahcall, Magda
    Oxnard, Geoffrey R.
    Eck, Michael J.
    Janne, Pasi A.
    CANCER RESEARCH, 2017, 77 (10) : 2712 - 2721
  • [8] EGFR and HER2 inhibition in pancreatic cancer
    Naomi Walsh
    Susan Kennedy
    AnneMarie Larkin
    Brendan Corkery
    Lorraine O’Driscoll
    Martin Clynes
    John Crown
    Norma O’Donovan
    Investigational New Drugs, 2013, 31 : 558 - 566
  • [9] EGFR and HER2 inhibition in pancreatic cancer
    Walsh, Naomi
    Kennedy, Susan
    Larkin, AnneMarie
    Corkery, Brendan
    O'Driscoll, Lorraine
    Clynes, Martin
    Crown, John
    O'Donovan, Norma
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) : 558 - 566
  • [10] Inhibition of HER2 tyrosine kinase disrupts androgen-receptor functioning
    Nature Clinical Practice Urology, 2005, 2 (6): : 264 - 265
12345